These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Neal-Beliveau BS; Joyce JN Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220 [TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
4. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat. Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576 [TBL] [Abstract][Full Text] [Related]
5. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Neal BS; Joyce JN Brain Res Dev Brain Res; 1991 Jun; 60(2):105-13. PubMed ID: 1832593 [TBL] [Abstract][Full Text] [Related]
6. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
8. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors. Yokoyama C; Okamura H J Pharmacol Exp Ther; 1997 Feb; 280(2):1016-30. PubMed ID: 9023319 [TBL] [Abstract][Full Text] [Related]
9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
10. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
11. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. Hess EJ; Albers LJ; Le H; Creese I J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223 [TBL] [Abstract][Full Text] [Related]
12. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists. McPherson RJ; Marshall JF Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899 [TBL] [Abstract][Full Text] [Related]
13. Comparative development of D1-dopamine and mu opiate receptors in normal and in 6-hydroxydopamine-lesioned neonatal rat striatum: dopaminergic fibers regulate mu but not D1 receptor distribution. Caboche J; Rogard M; Besson MJ Brain Res Dev Brain Res; 1991 Jan; 58(1):111-22. PubMed ID: 1849802 [TBL] [Abstract][Full Text] [Related]
14. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. Hu XT; Wachtel SR; Galloway MP; White FJ J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947 [TBL] [Abstract][Full Text] [Related]
15. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Frohna PA; Rothblat DS; Joyce JN; Schneider JS Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343 [TBL] [Abstract][Full Text] [Related]
16. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. Thomas WS; Neal-Beliveau BS; Joyce JN Brain Res Dev Brain Res; 1998 Nov; 111(1):99-106. PubMed ID: 9804909 [TBL] [Abstract][Full Text] [Related]
17. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment. Joyce JN Exp Neurol; 1991 Sep; 113(3):277-90. PubMed ID: 1833220 [TBL] [Abstract][Full Text] [Related]
18. Limbic pallidal adaptations following long-term cessation of dopaminergic transmission: lack of upregulation of dopamine receptor function. Heidenreich BA; Mitrovic I; Battaglia G; Napier TC Exp Neurol; 2004 Apr; 186(2):145-57. PubMed ID: 15026253 [TBL] [Abstract][Full Text] [Related]
19. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. Criswell HE; Johnson KB; Mueller RA; Breese GR J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756 [TBL] [Abstract][Full Text] [Related]
20. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems. Wachtel SR; Hu XT; Galloway MP; White FJ Synapse; 1989; 4(4):327-46. PubMed ID: 2532422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]